Therefore, MCT1, MCT2, and MCT4 are over-expressed in many different types of cancers and tumors, and, thus, targeting MCT-mediated lactate efflux could serve as a promising treatment or adjuvant therapy to other chemotherapeutics [160,161]. The gene discussed is SLC16A1; the disease is cancer.